ArticleCureus2025
The Early Experience of Synchrony in Ultra-Hypofractionation for Prostate Cancer: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultra-hypofractionated radiotherapy has emerged as an effective treatment for localized prostate cancer, offering comparable oncologic outcomes to conventional fractionation while significantly reducing treatment duration. However, the delivery of high doses per fraction demands exceptional precision to minimize toxicity risks, particularly in the context of intrafractional prostate motion. Real-time tracking systems, such as Synchrony (Accuray, Sunnyvale, CA, USA), aim to address this challenge by continuously monitoring and correcting for target displacement during beam delivery. This study evaluates the technical feasibility and early clinical outcomes of ultra-hypofractionated radiotherapy (36.25 Gy in five fractions) delivered with Synchrony real-time tracking, with specific analysis of prostate specific antigen (PSA) kinetics, treatment delivery parameters, and safety. Five consecutive patients received fiducial-based radiotherapy with continuous motion tracking. PSA levels were monitored during the first two months post-treatment. Treatment efficiency metrics (including beam interruptions and motion events) and acute toxicity (Common Terminology Criteria for Adverse Events (CTCAE) v5.0) were prospectively recorded. A rapid biochemical response was observed, with a mean PSA decline rate of -4.27 ng/mL/month. System performance demonstrated stable rigid-body tracking with a median deviation of 1.04 mm (IQR: 0.74 to 1.39 mm), and clinically acceptable posterior displacement in the Z-axis with a median of -1.54 mm (IQR: -2.80 to -0.38 mm). The composite 3D target offset had a median of 2.52 mm (IQR: 1.53 to 3.30 mm). Automatic pauses occurred when motion exceeded safety thresholds, increasing mean treatment duration by 13.9% (actual: 586.5 seconds vs. planned: 514.9 seconds). Despite systematic posterior tracking offsets, toxicity was minimal (one grade 1 GI event). Synchrony tracking enabled precise ultra-hypofractionated delivery with submillimeter accuracy and minimal toxicity. The modest increase in treatment time is a justifiable trade-off for real-time motion adaptation. These early results support further investigation into Synchrony-optimized prostate ultra-hypofractionated radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.